Partners
The work we do at CANN is immensely important, but without the support of other organizations with similar goals our efforts would not be nearly as meaningful. A combination of non-profit and government organizations (Community Affiliates), and pharmaceutical companies (Industry Affiliates) engage members of Congress with us, through coalitions and working groups, to instigate the creation, implementation, and maintenance of meaningful HIV/AIDS policy. By confronting our nation's leaders as a unified group we are able to bring about necessary changes to benefit the underserved and underrepresented individuals that are in need of treatment.
Our Community partners come from a variety of health related focuses. Whether they specialize in housing programs, infectious disease, prevention, or serving low income underserved populations, we all agree that HIV/AIDS should be a necessary focus for our government. With the advancements in treatment since HIV/AIDS first emerged in the early 1980's, HIV infected individuals are capable of managing the disease as a chronic illness as opposed to a fatal disease. Unfortunately not all HIV+ Americans are capable of paying for medications. We strive to ensure all Americans in need of treatment are capable of receiving it. After all, treatment of HIV is prevention. Click here to see a list of community partners.
The Pharmaceutical Industry has played a significant role facilitating access to medications through ADAP over the last six years. As the federal share of the ADAP Earmark has decreased, pharmaceutical discounts and rebates have increased to sustain the program. In 2009 pharmaceutical rebates accounted for approximately 30% of ADAP funding, as well as saving the US government over $1 billion through pharmaceutical discounts. In the recent economic recession many pharmaceutical companies have united to grant HIV infected individuals access to medications when they have been put on ADAP waiting lists, free of charge with minimal hassle. Click here to see a list of our pharmaceutical industry partners.
